FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies
Source: Pixabay.com

FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies

According to a recent press release from biopharmaceutical company Praxis Precision Medicines ("Praxis"), two of the company's drug candidates received either Orphan Drug or Rare Pediatric Disease designations for rare…

Continue Reading FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies
Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
source: pixabay.com

Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma

  A recent announcement by Gilead Company citing data from Kite Pharma, one of its premier companies, set out remarkable results from Kite’s Zuma-1 clinical trial. The findings confirmed that…

Continue Reading Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
source: pixabay.com

Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay

As reported in PR NewsWire;  in an effort to help the entirety of the sickle cell disease community, Emmaus Life Sciences, Inc has announced a program that will provide their…

Continue Reading Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay